BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/14/2018 5:07:58 AM | Browse: 497 | Download: 223
Publication Name World Journal of Gastroenterology
Manuscript ID 36349
Country/Territory Denmark
2017-09-25 17:28
Peer-Review Started
2017-09-25 17:32
To Make the First Decision
2017-11-03 05:36
Return for Revision
2017-11-03 18:39
2017-11-24 18:26
Second Decision
2017-12-04 09:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-12-04 20:00
Articles in Press
2017-12-04 20:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-01-08 07:31
Publish the Manuscript Online
2018-01-14 05:07
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research and Experimental
Manuscript Type Basic Study
Article Title Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
Manuscript Source Unsolicited Manuscript
All Author List Kirstine Sloth Tølbøl, Maria NB Kristiansen, Henrik H Hansen, Sanne S Veidal, Kristoffer T G Rigbolt, Matthew P Gillum, Jacob Jelsing, Niels Vrang and Michael Feigh
Author(s) ORCID Number
Kirstine Sloth Tølbøl http://orcid.org/0000-0001-6817-7441
Maria NB Kristiansen http://orcid.org/0000-0001-8732-3977
Henrik H Hansen http://orcid.org/0000-0002-3732-0281
Sanne S Veidal http://orcid.org/0000-0003-1240-2034
Kristoffer T G Rigbolt http://orcid.org/0000-0002-9470-0993
Matthew P Gillum http://orcid.org/0000-0003-4893-012X
Jacob Jelsing http://orcid.org/0000-0002-4583-1022
Niels Vrang http://orcid.org/0000-0002-7203-9532
Michael Feigh http://orcid.org/0000-0001-5274-8799
Funding Agency and Grant Number
Funding Agency Grant Number
Innovation Fund Denmark 5016-00168B
Innovation Fund Denmark 5189-00040B
Corresponding author Kirstine Sloth Tølbøl, MSc, Research Scientist, Pharmacology research, Gubra Aps, Hørsholm Kongevej 11b, Hørsholm 2970, Denmark. kst@gubra.dk
Keywords Nonalcoholic steatohepatitis; Disease models; Pathology; Fibrosis; Liver biopsy; Transcriptomics; Pharmacodynamics; Glucagon-like peptide-1 receptor; Peroxisome proliferator-activated receptor; Farnesoid X receptor
Core Tip The pharmacodynamics of three compounds in advanced clinical development for the treatment of nonalcoholic steatohepatitis (NASH), including liraglutide, elafibranor and obeticholic acid, were evaluated in wild-type and genetically (ob/ob) obese mouse models of NASH. Prior to treatment, all mice underwent liver biopsy for confirmation and stratification of liver steatosis and fibrosis. Within-subject comparisons were performed on changes in liver histopathology. Wild-type and ob/ob-NASH obese mice showed distinct treatment effects of liraglutide, OCA, and elafibranor, being in general agreement with corresponding findings in clinical trials for NASH. In conclusion, the two obese mouse models of NASH show clinical translatability with respect to disease etiology, histopathology and drug treatment effects, which supports their utility in preclinical drug development.
Publish Date 2018-01-14 05:07
Citation Tølbøl KS, Kristiansen MNB, Hansen HH, Veidal SS, Rigbolt KTG, Gillum MP, Jelsing J, Vrang N, Feigh M. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 179-194
Url http://www.wjgnet.com/1007-9327/full/v24/i2/179.htm
DOI http://dx.doi.org/10.3748/wjg.v24.i2.179
Full Article (PDF) WJG-24-179.pdf
Full Article (Word) WJG-24-179.doc
Manuscript File 36349-Review.docx
Answering Reviewers 36349-Answering reviewers.pdf
Audio Core Tip 36349-Audio core tip.m4a
Biostatistics Review Certificate 36349-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 36349-Conflict-of-interest statement.pdf
Copyright License Agreement 36349-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 36349-Grant application form(s).pdf
Institutional Animal Care and Use Committee Approval Form or Document 36349-Institutional animal care and use committee statement.pdf
Supplementary Material 36349-Supplementary-Material-revision.docx
Peer-review Report 36349-Peer-review(s).pdf
Scientific Editor Work List 36349-Scientific editor work list.pdf